 NEW YORK, Jan. 15, 2021 PRNewswire -- Seelos Therapeutics, Inc. Nasdaq: SEEL, a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first patients in its registrational... 